-
公开(公告)号：US20080199438A1
公开(公告)日：2008-08-21
申请号：US10598947
申请日：2005-03-15
IPC分类号： A61K48/00 , A61K31/7105 , A61K38/02 , A61P35/00
CPC分类号： A61K38/179 , C12N15/1136 , C12N2310/11 , C12N2310/14
摘要： The present invention provides methods for suppressing tumor proliferation comprising the step of inhibiting the expression of PDGF-A or the binding between PDGF-A homodimers and PDGFRα. Activation of the PDGFRα-p70S6K signal transduction pathway by PDGF-AA is an important factor in tumor angiogenesis and relates to the prognosis of patients suffering from tumors. By inhibiting PDGF-A expression in tumors or in their surrounding tissues, or by inhibiting the binding between PDGF-A homodimers and PDGFRα, the formation and retention of tumor vasculature can be inhibited, thereby suppressing tumor proliferation.
摘要翻译： 本发明提供了抑制肿瘤增殖的方法，包括抑制PDGF-A的表达或PDGF-A同源二聚体与PDGFRα之间的结合的步骤。 通过PDGF-AA激活PDGFRα-p70S6K信号转导途径是肿瘤血管生成中的重要因素，涉及肿瘤患者的预后。 通过抑制肿瘤或其周围组织中的PDGF-A表达，或通过抑制PDGF-A同源二聚体和PDGFRα之间的结合，可以抑制肿瘤血管的形成和保留，从而抑制肿瘤的增殖。
-
公开(公告)号：US20080031855A1
公开(公告)日：2008-02-07
申请号：US11630522
申请日：2005-04-28
申请人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
发明人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
CPC分类号： A61K35/76 , A61K35/768 , A61K38/179 , A61K38/215 , A61K2039/5154 , C12N2760/18832 , C12N2760/18871
摘要： Minus-strand RNA viruses were found to have an effective tumor-suppressive effect even when they did not carry a therapeutically effective gene. The present invention provides anticancer agents comprising a minus-strand RNA virus. Furthermore, the present invention provides methods for producing the anticancer agents, which comprise the step of mixing a minus-strand RNA virus with pharmaceutically acceptable carriers. Furthermore, the present invention provides methods for suppressing cancer, which comprise the step of administering a minus-strand RNA virus to cancer tissues.
摘要翻译： 发现减数RNA病毒即使不携带治疗有效的基因也具有有效的肿瘤抑制作用。 本发明提供了包含负链RNA病毒的抗癌剂。 此外，本发明提供了制造抗癌剂的方法，其包括将负链RNA病毒与药学上可接受的载体混合的步骤。 此外，本发明提供了抑制癌症的方法，其包括向癌组织施用负链RNA病毒的步骤。
-
公开(公告)号：US20070269414A1
公开(公告)日：2007-11-22
申请号：US10578085
申请日：2004-10-29
CPC分类号： C12N15/86 , A61K2039/5156 , C12N2510/02 , C12N2760/18843
摘要： The present invention provides a method for introducing a gene into a dendritic cell, which includes the step of contacting a minus-strand RNA virus with a dendritic cell. The present invention also provides a method for producing a gene transferred dendritic cell, which includes the step of contacting a minus-strand RNA virus with a dendritic cell. The present invention also provides gene transferred dendritic cells produced by such methods. Furthermore, the present invention provides a method for activating a dendritic cell, which includes the step of contacting a minus-strand RNA virus with a dendritic cell. The present invention enables efficient gene delivery into dendritic cells. Dendritic cells introduced with antigen gene or cytokine gene are useful as vaccine.
摘要翻译： 本发明提供了将基因导入树状细胞的方法，其包括使负链RNA病毒与树突状细胞接触的步骤。 本发明还提供了一种转基因树突状细胞的制备方法，其包括将负链RNA病毒与树突状细胞接触的步骤。 本发明还提供了通过这些方法产生的基因转移的树突状细胞。 此外，本发明提供了激活树突细胞的方法，其包括使负链RNA病毒与树突状细胞接触的步骤。 本发明使得有效的基因递送到树突状细胞中。 引入抗原基因或细胞因子基因的树突状细胞可用作疫苗。
-
公开(公告)号：US08211868B2
公开(公告)日：2012-07-03
申请号：US13049011
申请日：2011-03-16
申请人： Yoshikazu Yonemitsu , Katsuo Sueishi , Masayuki Fukumura , Xiaogang Hou , Mamoru Hasegawa , Hidenori Matsusaka , Hiroyuki Tsutsui
发明人： Yoshikazu Yonemitsu , Katsuo Sueishi , Masayuki Fukumura , Xiaogang Hou , Mamoru Hasegawa , Hidenori Matsusaka , Hiroyuki Tsutsui
IPC分类号： A61K48/00
CPC分类号： C12N15/86 , A61K48/00 , C07K14/50 , C12N2760/18843 , C12N2800/30
摘要： The present invention provides Paramyxovirus vectors encoding angiogenic genes and use of the same. The use of Paramyxovirus vectors enables effective transfer of angiogenic genes into individual tissues. FGF2 gene transferred into ischemic tissues in vivo induces expression of angiogenic genes without causing edema, and prevents necrosis due to ischemia. The vectors of the present invention are suitable for gene therapy targeted to ischemic tissues.
摘要翻译： 本发明提供编码血管生成基因的副粘病毒载体及其用途。 使用副粘病毒载体能够有效地将血管生成基因转移到单个组织中。 FGF2基因在体内转移到缺血组织中诱导血管生成基因的表达而不引起水肿，并且防止由缺血引起的坏死。 本发明的载体适合于靶向缺血组织的基因治疗。
-
5.发明申请Anticancer Agent Containing Dendritic Cell Having Rna Virus Transferred Thereinto 有权含有转移Rna病毒的树突状细胞的抗癌剂公开(公告)号：US20080014183A1
公开(公告)日：2008-01-17
申请号：US11630532
申请日：2005-04-28
申请人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
发明人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
IPC分类号： A61K48/00
CPC分类号： A61K35/76 , A61K35/768 , A61K38/179 , A61K38/215 , A61K2039/5154 , C12N2760/18832 , C12N2760/18871
摘要： The present invention provides anticancer agents comprising dendritic cells introduced with RNA viruses. The present invention also provides methods for producing anticancer agents, which comprise the step of preparing dendritic cells introduced with RNA viruses. The present invention also provides methods for treating cancers using dendritic cells introduced with RNA viruses. The present invention provides effective methods for treating cancers, which use RNA viruses and dendritic cells in combination
摘要翻译： 本发明提供包含引入RNA病毒的树突状细胞的抗癌剂。 本发明还提供了制备抗癌剂的方法，其包括制备引入RNA病毒的树突状细胞的步骤。 本发明还提供了用RNA病毒引入的树突状细胞治疗癌症的方法。 本发明提供了组合使用RNA病毒和树突状细胞的治疗癌症的有效方法
-
6.发明授权Therapeutic agents for diseases associated with apoptotic degeneration in ocular tissue cells that use SIV-PEDF vectors 有权与使用SIV-PEDF载体的眼组织细胞凋亡变性相关疾病的治疗剂公开(公告)号：US08278284B2
公开(公告)日：2012-10-02
申请号：US11884738
申请日：2006-02-21
申请人： Masanori Miyazaki , Yoshikazu Yonemitsu , Yasuhiro Ikeda , Katsuo Sueishi , Toshiaki Tabata , Akihiro Iida , Yasuji Ueda , Mamoru Hasegawa
发明人： Masanori Miyazaki , Yoshikazu Yonemitsu , Yasuhiro Ikeda , Katsuo Sueishi , Toshiaki Tabata , Akihiro Iida , Yasuji Ueda , Mamoru Hasegawa
CPC分类号： A61K48/005 , A61K48/00 , C07K14/475 , C12N15/86 , C12N2740/15043 , C12N2740/15045 , C12N2810/6081
摘要： The present invention provides novel methods for treating diseases associated with apoptotic degeneration in ocular tissue cells by effective administration of pigment epithelium derived factor (PEDF). The present inventors studied PEDF as a means to prevent ganglion cell death, the final pathology of glaucoma. The present invention is particularly focused on SIV vectors for effective methods for delivering PEDF, and constructed an SIV-PEDF vector. When the SIV-PEDF vector was administered subretinally to an ischemia reperfusion model and NMDA-induced model, a significant suppression effect on ganglion cell death was observed. The present inventors therefore discovered that the SIV-PEDF vector is an effective pharmaceutical agent for treating diseases associated with apoptotic degeneration in ocular tissue cells, such as glaucoma.
摘要翻译： 本发明提供了通过有效施用色素上皮衍生因子（PEDF）来治疗与眼组织细胞凋亡变性相关的疾病的新方法。 本发明人研究了PEDF作为预防神经节细胞死亡，青光眼的最终病理学的手段。 本发明特别关注用于递送PEDF的有效方法的SIV载体，并构建了SIV-PEDF载体。 当将SIV-PEDF载体视觉上给予缺血再灌注模型和NMDA诱导的模型时，观察到对神经节细胞死亡的显着抑制作用。 因此本发明人发现SIV-PEDF载体是用于治疗与眼组织细胞如青光眼中凋亡变性相关的疾病的有效药剂。
-
7.发明申请Therapeutic Agents for Diseases Associated With Apoptotic Degeneration in Ocular Tissue Cells That Use SIV-PEDF Vectors 有权与使用SIV-PEDF载体的组织细胞凋亡相关的疾病治疗剂公开(公告)号：US20090233988A1
公开(公告)日：2009-09-17
申请号：US11884738
申请日：2006-02-21
申请人： Masanori Miyazaki , Yoshikazu Yonemitsu , Yasuhiro Ikeda , Katsuo Sueishi , Toshiaki Tabata , Akihiro Iida , Yasuji Ueda , Mamoru Hasegawa
发明人： Masanori Miyazaki , Yoshikazu Yonemitsu , Yasuhiro Ikeda , Katsuo Sueishi , Toshiaki Tabata , Akihiro Iida , Yasuji Ueda , Mamoru Hasegawa
IPC分类号： A61K31/711 , C12N15/63 , C12N7/01
CPC分类号： A61K48/005 , A61K48/00 , C07K14/475 , C12N15/86 , C12N2740/15043 , C12N2740/15045 , C12N2810/6081
摘要： The present invention provides novel methods for treating diseases associated with apoptotic degeneration in ocular tissue cells by effective administration of pigment epithelium derived factor (PEDF). The present inventors studied PEDF as a means to prevent ganglion cell death, the final pathology of glaucoma. The present invention is particularly focused on SIV vectors for effective methods for delivering PEDF, and constructed an SIV-PEDF vector. When the SIV-PEDF vector was administered subretinally to an ischemia reperfusion model and NMDA-induced model, a significant suppression effect on ganglion cell death was observed. The present inventors therefore discovered that the SIV-PEDF vector is an effective pharmaceutical agent for treating diseases associated with apoptotic degeneration in ocular tissue cells, such as glaucoma.
摘要翻译： 本发明提供了通过有效施用色素上皮衍生因子（PEDF）来治疗与眼组织细胞凋亡变性相关的疾病的新方法。 本发明人研究了PEDF作为预防神经节细胞死亡，青光眼的最终病理学的手段。 本发明特别关注用于递送PEDF的有效方法的SIV载体，并构建了SIV-PEDF载体。 当将SIV-PEDF载体视觉上给予缺血再灌注模型和NMDA诱导的模型时，观察到对神经节细胞死亡的显着抑制作用。 因此本发明人发现SIV-PEDF载体是用于治疗与眼组织细胞如青光眼中凋亡变性相关的疾病的有效药剂。
-
8.发明授权Anticancer agent containing dendritic cell having RNA virus transferred thereinto 有权含有转录有RNA病毒的树突状细胞的抗癌剂公开(公告)号：US08889118B2
公开(公告)日：2014-11-18
申请号：US11630532
申请日：2005-04-28
申请人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
发明人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
CPC分类号： A61K35/76 , A61K35/768 , A61K38/179 , A61K38/215 , A61K2039/5154 , C12N2760/18832 , C12N2760/18871
摘要： The present invention provides anticancer agents comprising dendritic cells introduced with RNA viruses. The present invention also provides methods for producing anticancer agents, which comprise the step of preparing dendritic cells introduced with RNA viruses. The present invention also provides methods for treating cancers using dendritic cells introduced with RNA viruses. The present invention provides effective methods for treating cancers, which use RNA viruses and dendritic cells in combination.
摘要翻译： 本发明提供包含引入RNA病毒的树突状细胞的抗癌剂。 本发明还提供了制备抗癌剂的方法，其包括制备引入RNA病毒的树突状细胞的步骤。 本发明还提供了用RNA病毒引入的树突状细胞治疗癌症的方法。 本发明提供了组合使用RNA病毒和树突状细胞的治疗癌症的有效方法。
-
公开(公告)号：US20060104950A1
公开(公告)日：2006-05-18
申请号：US10532172
申请日：2003-10-22
CPC分类号： C12N15/86 , C12N2760/18843 , C12N2800/30
摘要： The present invention provides methods of transducing a gene into activated T cells comprising the step of contacting a paramyxovirus vector with activated T cells. This invention also provides a method of preparing T cells transduced with a foreign gene comprising the step of contacting a paramyxovirus vector with activated T cells. This invention also provides T cells transduced with a foreign gene prepared by this method. The present invention enables efficient gene transduction specific to activated T cells, and is expected to be applied to immunological modification strategies using T cell-directed gene delivery.
摘要翻译： 本发明提供将基因转导到活化的T细胞中的方法，包括使副粘病毒载体与活化的T细胞接触的步骤。 本发明还提供了一种制备用外源基因转导的T细胞的方法，包括使副粘病毒载体与活化的T细胞接触的步骤。 本发明还提供了通过该方法制备的外源基因转导的T细胞。 本发明能够有效地对活化的T细胞进行基因转导，并且预期将其应用于使用T细胞定向基因递送的免疫修饰策略。
-
公开(公告)号：US07309693B2
公开(公告)日：2007-12-18
申请号：US10276971
申请日：2001-05-25
CPC分类号： C07K16/24 , A61K31/711 , A61K38/195 , A61K2039/505
摘要： The present invention provides a prophylactic and/or therapeutic agent for pulmonary hypertension, comprising an antagonistic mutein of MCP-1 or a salt thereof, a DNA molecule comprising a nucleotide sequence encoding the antagonistic mutein of MCP-1, or a neutralizing antibody against MCP-1. The antagonistic mutein of MCP-1 or a salt thereof, the DNA molecule having a nucleotide sequence encoding the antagonistic mutein of MCP-1, or the neutralizing antibody against MCP-1 has hypotensive activity, and thus is useful as a pharmaceutical agent for preventing and/or treating pulmonary hypertension (primary pulmonary hypertension, in particular).
摘要翻译： 本发明提供了一种肺动脉高压的预防和/或治疗剂，其包含MCP-1的拮抗性突变蛋白或其盐，包含编码MCP-1的拮抗性突变蛋白的核苷酸序列的DNA分子或针对MCP的中和抗体 -1。 MCP-1或其盐的拮抗性突变蛋白，具有编码MCP-1的拮抗性突变蛋白的核苷酸序列的DNA分子或针对MCP-1的中和抗体具有降血压活性，因此可用作预防药物 和/或治疗肺动脉高压（特别是原发性肺动脉高压）。
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.027 秒)
